Author:
Steinbild S,Mross K,Frost A,Morant R,Gillessen S,Dittrich C,Strumberg D,Hochhaus A,Hanauske A-R,Edler L,Burkholder I,Scheulen M
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–4300
2. Agus DB, Sweeny CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI (2007) Efficacy and safety of single agent pertuzumab (rhuMAB2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25: 675–681
3. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855–1861
4. Awada A, Hendlisz A, Whenham N, Gil T, Christensen O, Lathia C, Bartholomeus S, Delabaye I, de Valeriola D, Brendel E, Delaunoit T, Piccart M (2007) Phase I trial to evaluate safety, pharmacokinetics and efficacy of sorafenib with docetaxel in patients with advanced, refractory solid tumors. Ann Oncol 18 (Suppl 4): 401
5. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 25: 669–674
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献